NCT07252284 CHina Adrenal Venous saMPling InvestigatiON
| NCT ID | NCT07252284 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Hyperaldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2025-05-01 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.
Eligibility Criteria
Inclusion Criteria: 1. Patients with confirmed primary aldosteronism; 2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism. Exclusion Criteria: 1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months； 2. An estimated glomerular filtration rate \<45 ml/min/1.73 m2, or serum creatinine \>176 μmol/L； 3. Patients who refuse adrenalectomy; 4. Suspected of having an adrenocortical carcinoma; 5. Allergy to contrast agent; 6. Pregnant, nursing, or planning to become pregnant
Contact & Investigator
Hui Dong, MD
PRINCIPAL INVESTIGATOR
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Frequently Asked Questions
Who can join the NCT07252284 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperaldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07252284 currently recruiting?
Yes, NCT07252284 is actively recruiting participants. Contact the research team at donghui666@sina.com for enrollment information.
Where is the NCT07252284 trial being conducted?
This trial is being conducted at Hefei, China, Beijing, China, Beijing, China, Beijing, China and 11 additional locations.
Who is sponsoring the NCT07252284 clinical trial?
NCT07252284 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The principal investigator is Hui Dong, MD at Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College. The trial plans to enroll 5,000 participants.